Publications
Overview of publications related to PBCB
Monitoring of circulating tumour DNA allows early detection of disease relapse in patients with operable breast cancer. Mol Oncol. 2025 Nov 27.
This article discusses investigations of circulating tumour DNA from dying cancer cells in blood samples for possible early detection of disease relapse.
Quantitative proteomics reveals serum proteome alterations during metastatic disease progression in breast cancer patients. Clin Proteomics. 2024 Jul 29;21(1):52.
This study used advanced proteomics (mass spectrometry) to measure hundreds of proteins in blood serum in breast cancer patients and compared those who later developed distant metastases with those who did not.
Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. 2023 Jul 4;23(1):625.
This article is a systematic review of previous research on what happens if women with hormone receptor-positive breast cancer do not take their prescribed hormone therapy as they should (either because they skip doses or stop too early).
Simultaneous Quantification of Aromatase Inhibitors and Oestrogens in Postmenopausal Breast Cancer Patients. The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 5, May 2022, Pages 1368–1374.
The article describes the development of a new laboratory method that can measure the levels of all common aromatase inhibitors (letrozole, anastrozole, and exemestane) as well as very low amounts of oestrogen in the blood of postmenopausal breast cancer patients receiving aromatase inhibitor treatment. This provides researchers and clinicians with an opportunity to monitor whether the treatment is effective and whether the patient is actually taking their medications.
This is the study protocol for PBCB, which provides a detailed description of methods for collecting biological, clinical, and patient-reported data. The protocol also describes the patient population and the main objectives of the biobanking project.
Here, a high-sensitivity bioanalytical method for measuring oestrogens and aromatase inhibitors in human serum is described. Serum from postmenopausal PBCB patients who used aromatase inhibitors was used to validate the method.
Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
In this study, tamoxifen concentrations and genotypes from PBCB patients were used to investigate how the metabolism of tamoxifen is related to genetic variation in the enzymes that break down tamoxifen:
These three articles mapped the extent to which patients adhere to endocrine treatment as prescribed (adherence to tamoxifen treatment). Self-reported adherence, data from the prescription register, and direct measurements of tamoxifen in the blood were used to determine and compare adherence. The studies also recorded side effects and attempted to identify clinical and biochemical factors associated with the occurrence of side effects
Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumour proliferation and clinical outcome in breast cancer patients ─ a randomized trial. BMC Cancer. 2019 Nov 8;19(1):1076.
This study investigates whether drinking sugary nutrition before breast cancer surgery, instead of fasting, can affect the growth of cancer cells and the patients' prognosis.
Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study. BMC Cancer. 2019 Dec 4;19(1):1183.
This study looks at what happens inside the body and in the tumour itself when breast cancer patients receive a sugary drink before surgery instead of fasting.
Diet in women with breast cancer compared to healthy controls - What is the difference?
Here, the diet of breast cancer patients was examined two years after diagnosis compared to healthy controls. The study was published in 2017.
In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol. 2011 Mar 1;29(7):852-8. Epub 2010 Dec 28.
This study investigates whether Mitotic Activity Index (MAI), which provides a measure of how quickly cancer cells divide, is better at predicting prognosis than the software program Adjuvant! in women under 55 years with breast cancer without spread to lymph nodes.